A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease

Trial Profile

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Embolism and thrombosis; Sickle cell anaemia; Veno-occlusive disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms DOVE; TADO
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Dec 2016 Results published in the Thrombosis and Haemostasis
    • 06 Dec 2016 Results assessing effect of geographical region and age group on vaso-occlusive crisis (VOC) events, analgesic use, the rate, intensity, and perception of pain in children with sickle cell anaemia, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results assessing effect of geographic differences in phenotype on baseline clinical, laboratory characteristics and study endpoints in multinational DOVE study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top